We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 126 for:    "Frontotemporal dementia"

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01890343
Recruitment Status : Completed
First Posted : July 1, 2013
Results First Posted : September 17, 2014
Last Update Posted : September 29, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Frontotemporal Dementia Drug: florbetapir 18F Drug: 18F-FDG Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.
Study Start Date : September 2009
Primary Completion Date : December 2012
Study Completion Date : April 2013


Arms and Interventions

Arm Intervention/treatment
Experimental: Frontotemporal Disorder
Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
Drug: florbetapir 18F
Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Other Names:
  • Florbetapir F 18
  • 18F-AV-45
  • Amyvid
Drug: 18F-FDG
FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
Other Names:
  • FDG
  • fluorodeoxyglucose (18F)
  • fludeoxyglucose (18F)
Experimental: Cognitively Normal
Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Drug: florbetapir 18F
Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Other Names:
  • Florbetapir F 18
  • 18F-AV-45
  • Amyvid
Experimental: Alzheimer's Disease
Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Drug: florbetapir 18F
Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Other Names:
  • Florbetapir F 18
  • 18F-AV-45
  • Amyvid


Outcome Measures

Primary Outcome Measures :
  1. Qualitative Amyloid Image Assessment [ Time Frame: 50-60 min after injection ]
    Four readers blinded to all clinical information classified florbetapir Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read classification is presented as either positive, negative or tied.

  2. Quantitative Amyloid Image Assessment [ Time Frame: 50-60 minutes after injection ]
    The effect of diagnostic group on mean total cortical grey matter florbetapir binding relative to cerebellar cortex is presented as standard uptake value ratios (SUVr).


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

AD:

  • Male or female >= 50 years of age
  • Meet National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive
  • Have a caregiver who can report on their mental status and activities of daily living (ADL)
  • Give informed consent or have a caregiver give consent with subject assent.

FTD:

  • Male or female >= 45 years of age
  • Meet consensus criteria for FTD and have mild to moderate disease severity. Have a caregiver who can report on their mental status and ADL
  • Give informed consent or have a caregiver give consent with subject assent.

CN:

  • Male or female >= 45 years of age
  • Have and MMSE >= 29
  • Give informed consent

Exclusion Criteria:

  • Have a history or a current clinically significant neurologic disease (other than AD or FTD, as applicable), a diagnosis of other dementing/neurodegenerative disease, or a diagnosis of mixed dementia
  • Evidence from MRI or other biomarkers that suggests an etiology of dementia other than AD or FTD, as applicable or in the case of CN subjects evidence indicating the presence of AD, FTD or other types of neurologic pathology
  • Have current clinically significant cardiovascular disease, screening ECG abnormalities, psychiatric disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, cancer or infectious disease
  • Have a recent history of alcohol or substance abuse or dependence
  • Women of childbearing potential who are not permanently surgically sterile, or are not refraining from sexual activity while not using adequate contraception.
  • Require medications with a narrow therapeutic window, are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days
  • Have ever participated in a study with an amyloid targeting agent
  • Have had a radiopharmaceutical imaging or treatment procedure within 7 days of the imaging, other than as defined in the protocol
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01890343


Locations
United Kingdom
Research Site
Manchester, United Kingdom, M20 3LJ
Sponsors and Collaborators
Avid Radiopharmaceuticals
Investigators
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
More Information

Responsible Party: Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier: NCT01890343     History of Changes
Other Study ID Numbers: 18F-AV-45-010
First Posted: July 1, 2013    Key Record Dates
Results First Posted: September 17, 2014
Last Update Posted: September 29, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Frontotemporal Dementia
Pick Disease of the Brain
Alzheimer Disease
Dementia
Aphasia, Primary Progressive
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Aphasia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action